<bill session="115" type="h" number="1840" updated="2017-07-15T07:15:54Z">
  <state datetime="2017-03-30">REFERRED</state>
  <status>
    <introduced datetime="2017-03-30"/>
  </status>
  <introduced datetime="2017-03-30"/>
  <titles>
    <title type="short" as="introduced">Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017</title>
    <title type="short" as="introduced">Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to allow a credit against tax for clinical testing expenses for qualified infectious disease drugs and rapid diagnostic tests.</title>
    <title type="display">Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017</title>
  </titles>
  <sponsor id="412303"/>
  <cosponsors>
    <cosponsor id="412477" joined="2017-07-14"/>
    <cosponsor id="400122" joined="2017-06-07"/>
    <cosponsor id="400124" joined="2017-05-23"/>
    <cosponsor id="400160" joined="2017-03-30"/>
    <cosponsor id="400350" joined="2017-03-30"/>
    <cosponsor id="400373" joined="2017-03-30"/>
    <cosponsor id="400403" joined="2017-03-30"/>
    <cosponsor id="412214" joined="2017-03-30"/>
  </cosponsors>
  <actions>
    <action datetime="2017-03-30">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-03-30" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Income tax credits"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Medical tests and diagnostic methods"/>
  </subjects>
  <amendments/>
  <summary date="2017-03-30T04:00:00Z" status="Introduced in House">Reinvigorating Antibiotic and Diagnostic Innovation Act of 2017

This bill amends the Internal Revenue Code to allow tax credits for 50% of the clinical testing expenses for: (1) infectious disease products that are intended to treat a serious or life-threatening infection, including one caused by an antibacterial or antifungal resistant pathogen or a qualifying pathogen listed by the Department of Health and Human Services as having the potential to pose a serious threat to public health; and (2) in-vitro diagnostic devices that identify in less than four hours the presence, concentration, or characteristics of a serious or life-threatening infection.</summary>
  <committee-reports/>
</bill>
